Clinical trials: Neoplasms by Site
Head Cancer Neck
Evaluation of Oncoxin-Viusid® in Head and Neck Cancer
Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors.
- Trial name
- NCT03541772
- Testing
- Oncoxin-Viusid®
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Breast Cancer
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic…
- Trial name
- DESTINY-B12 (NCT04739761)
- Testing
- Trastuzumab Deruxtecan
- Where
- 81 sites in United States, Australia and 16 more
- Volunteers
- 506 people
- Sponsor
- AstraZeneca
Solid Tumors, Pancreatic Cancer
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
- Trial name
- NCT01858883
- Testing
- itacitinib, Gemcitabine, nab-paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Breast Cancer (Locally Advanced or Metastatic)
GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
This is a Phase Ib/II, open-label, multi-cohort, multi-center study to evaluate the safety, tolerability, and preliminary anti-tumor activity of GB268, a biological product, as monotherapy or in combination with other therapies…
- Trial name
- NCT07738341
- Testing
- GB268, Nab-Paclitaxel, Datopotamab Deruxtecan (Dato-DXd)
- Volunteers
- 270 people
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Brain Tumor
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system.
- Trial name
- NCT00147056
- Testing
- ExAblate transcranial system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- InSightec
Melanoma
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the…
- Trial name
- NCT07091695
- Testing
- Nivolumab + relatlimab, Nivolumab + ipilimumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Urologic Neoplasms
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell…
- Trial name
- NCT00034177
- Testing
- S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel
- Volunteers
- 27 people
- Sponsor
- Achieve Life Sciences
Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer
A Study of DS-3939a in Participants With Solid Tumors
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
- Conditions
- Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07739966
- Testing
- DS-3939a, Pembrolizumab, Carboplatin
- Where
- 76 sites in United States, Argentina and 11 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor, Adult Disease
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Adult Disease, Lung Cancer
- Trial name
- ANV419-001 (NCT04855929)
- Testing
- ANV419, Ipilimumab
- Where
- 5 sites in Spain, Switzerland and 1 more
- Volunteers
- 55 people
- Sponsor
- Anaveon AG
Metastatic Pancreatic Cancer
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients…
- Trial name
- NCT06532331
- Testing
- ONO-7475, ONO-4538, Nab-paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Small-cell Lung Cancer
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg).
- Trial name
- PASSION (NCT03417895)
- Testing
- SHR-1210, Apatinib
- Where
- 2 sites in China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Breast Carcinoma
Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
The objective of this study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line…
- Trial name
- NCT05505175
- Where
- 14 sites in Brazil
- Volunteers
- 121 people
- Sponsor
- Pfizer
Malignant Melanoma
A Pilot Study of Pivanex in Patients With Malignant Melanoma
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
- Trial name
- NCT00087477
- Testing
- Pivanex
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Titan Pharmaceuticals
Malignant Melanoma
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
This study aims to evaluate safety and effect of combining an oncolytic adenovirus (delolimogene mupadenorepvec; LOAd703) with atezolizumab in patients with melanoma.
- Trial name
- NCT04123470
- Testing
- delolimogene mupadenorepvec, atezolizumab
- Where
- 3 sites in United States, Sweden
- Volunteers
- 24 people
- Sponsor
- Lokon Pharma AB
Colorectal Neoplasms
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
This is an open-label, non-randomized, prospective, multicentric, Phase IV study evaluating FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type metastatic CRC.
- Trial name
- NCT01134666
- Testing
- Cetuximab
- Where
- 40 sites in India
- Volunteers
- 165 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer (CRC)
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer
- Trial name
- NCT00851045
- Testing
- Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional)
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
- Trial name
- NCT06922539
- Testing
- Fenretinide
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- SciTech Development, Inc.
Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid…
- Conditions
- Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
- Trial name
- NCT03920839
- Testing
- Retifanlimab, Gemcitabine, Cisplatin
- Sponsor
- Incyte Corporation
Thyroid Cancer
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily…
- Trial name
- NCT02702388
- Testing
- Lenvatinib
- Where
- 101 sites in United States, Australia and 14 more
- Volunteers
- 241 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumor, Ovarian Cancer
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Trial name
- NCT05103683
- Testing
- TORL-1-23
- Where
- 14 sites in United States, South Korea
- Volunteers
- 90 people
- Sponsor
- TORL Biotherapeutics, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.